Jyong Biotech (NASDAQ:MENS) Shares Down 6.7% - Here's Why

Key Points

• Jyong Biotech Ltd. shares dropped 6.7% on Monday, closing at $41.73 after trading as low as $40.00.
• Trading volume decreased significantly, with 13,166 shares exchanged, which is a 94% drop from the average session volume of 204,032 shares.
• Wall Street Zen has upgraded Jyong Biotech to a "hold" rating in a recent research report.

Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report) shares traded down 6.7% on Monday . The company traded as low as $40.00 and last traded at $41.73. 13,166 shares changed hands during trading, a decline of 94% from the average session volume of 204,032 shares. The stock had previously closed at $44.74.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Jyong Biotech to a "hold" rating in a research report on Monday, June 30th.

Jyong Biotech Stock Down 7.2%

Jyong Biotech Company Profile

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers' health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.